Shire Buying ViroPharma To Create Leading Rare Disease Group
This article was originally published in The Pink Sheet Daily
Shire is snapping up ViroPharma at a hefty premium to secure possession of C1 esterase inhibitor Cinryze and position the group as a formidable force in treatments for rare diseases.
You may also be interested in...
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.